Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the companies' 2021 research collaboration. This marks Dyno’s second capsid licensed from its ...
Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying AI to empower patients everywhere with genetic agency, today announced the launch of Dyno Psi-Phi ...
The MarketWatch News Department was not involved in the creation of this content. -- Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the ...
Dyno’s Psi-Phi generative protein design and agentic interfaces provide versatile AI models and agents that connect physical outcomes with computational workflows Dyno Therapeutics, Inc., a genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results